Stocks Health care CABA
NASDAQ · Health careCabaletta Bio, Inc. (CABA)
It posted a net loss of $189.5M. In fiscal 2025 capital spending exceeded operating cash flow by $132.3M. At September 30, 2026 it held $299.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Cabaletta Bio, Inc.
- Net worth
- Cabaletta Bio, Inc. has a market value (market cap) of $254.3M at the latest share price, and shareholders' equity of $283.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $131.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cabaletta Bio, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Cabaletta Bio, Inc. does
Cabaletta Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CABA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$167.9M | -$2.10 | -$132.3M |
| 2024 | n/a | -$115.9M | -$2.34 | -$90.4M |
| 2023 | n/a | -$67.7M | -$1.65 | -$54.2M |
| 2022 | n/a | -$53M | -$1.81 | -$48.8M |
| 2021 | n/a | -$46.3M | -$1.80 | -$35.3M |
| 2020 | n/a | -$33.3M | -$1.44 | -$27.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cabaletta Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- November 5, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 14, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Cabaletta Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 21, 2026 | Gerard MichaelGeneral Counsel | Bought | 6,600 | $15K |
| January 21, 2026 | Simon MarkDirector | Bought | 11,061 | $25.3K |
| January 21, 2026 | Nichtberger StevenPresident & CEO, Director | Bought | 45,000 | $100.8K |
| January 21, 2026 | Bollard CatherineDirector | Bought | 4,405 | $10K |
| January 21, 2026 | Gavel SteveChief Commercial Officer | Bought | 22,170 | $50.2K |
| January 21, 2026 | Tomasello ShawnDirector | Boughtindirect | 22,725 | $50.3K |
| January 21, 2026 | Binder GwendolynPresident, Science & Tech. | Bought | 11,312 | $24.8K |
| January 21, 2026 | Chang David J.Chief Medical Officer | Bought | 8,800 | $19.9K |
Who owns CABA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 11.6% | August 14, 2026 |
| Jennison Associates LLC13G, passive | 11.4% | June 4, 2026 |
| Bain Capital Life Sciences Opportunities III, LP13G, passive | 9.99% | August 14, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 8.43% | August 12, 2026 |
| BlackRock, Inc.13G, passive | 7.7% | October 27, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 5.95% | August 14, 2026 |
| Norges Bank13G, passive | 5.38% | August 12, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 140 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jennison Associates LLC | 20,033,730 | +11,063,152 |
| Bain Capital Life Sciences Investors, LLC | 17,241,445 | +7,564,320 |
| BlackRock, Inc. | 10,754,701 | +8,381,698 |
| Adage Capital Partners GP, L.L.C. | 9,174,758 | +345,000 |
| State Street Corp | 7,839,305 | +7,369,327 |
| Vanguard Capital Management LLC | 7,227,018 | +3,198,027 |
| Cormorant Asset Management, LP | 5,000,000 | -500,000 |
| Woodline Partners LP | 4,200,142 | +2,949,900 |
| Norges Bank | 4,112,401 | new |
| Opaleye Management Inc. | 3,863,800 | +2,483,800 |
| Citadel Advisors LLC | 3,522,112 | new |
| Geode Capital Management, LLC | 3,459,464 | +2,326,219 |
| Franklin Resources Inc | 2,413,937 | new |
| Goldman Sachs Group Inc | 2,211,825 | +1,428,605 |
| Millennium Management LLC | 2,068,491 | -3,834,790 |
| Cantor Fitzgerald, L. P. | 1,600,002 | +835,002 |
| Marshall Wace, Llp | 1,565,939 | -613,879 |
| Renaissance Technologies LLC | 1,535,300 | -501,363 |
| UBS Group AG | 1,471,895 | +865,231 |
| Qube Research & Technologies Ltd | 1,426,840 | -508,150 |
Insiders
8 insiders reported holding 1,275,700 shares in total, about $1.9M at the last price.
| Holder | Shares |
|---|---|
| Nichtberger StevenPresident & CEO, Director | 1,031,483 |
| Simon MarkDirector | 147,205 |
| Binder GwendolynPresident, Science & Tech. | 31,312 |
| Tomasello ShawnDirector | 22,72522,725 held indirectly |
| Gavel SteveChief Commercial Officer | 22,170 |
| Chang David J.Chief Medical Officer | 8,800 |
| Gerard MichaelGeneral Counsel | 6,600 |
| Bollard CatherineDirector | 5,405 |
Questions about CABA
What does Cabaletta Bio, Inc. do?
Cabaletta Bio, Inc. is a company in the Health care sector, listed on NASDAQ as CABA. Its shares trade on NASDAQ under the ticker CABA.
What is Cabaletta Bio, Inc.'s net worth?
Cabaletta Bio, Inc. has a market value (market cap) of $254.3M at the latest share price, and shareholders' equity of $283.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cabaletta Bio, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $189.5M.
When did Cabaletta Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Cabaletta Bio, Inc.'s next earnings report?
Cabaletta Bio, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CABA with
Follow CABA
Get an email when Cabaletta Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cabaletta Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.